Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $615.9 million.

  • Keros Therapeutics' Liabilities and Shareholders Equity rose 28.23% to $742.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 53.45%. This contributed to the annual value of $615.9 million for FY2024, which is 66.44% up from last year.
  • As of FY2024, Keros Therapeutics' Liabilities and Shareholders Equity stood at $615.9 million, which was up 66.44% from $370.0 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Liabilities and Shareholders Equity registered a high of $615.9 million during FY2024, and its lowest value of $255.3 million during FY2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $370.0 million (2023), whereas its average is $430.9 million.
  • As far as peak fluctuations go, Keros Therapeutics' Liabilities and Shareholders Equity skyrocketed by 2,359.54% in 2020, and later dropped by 5.27% in 2021.
  • Keros Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $269.4 million in 2020, then dropped by 5.27% to $255.3 million in 2021, then rose by 20.19% to $306.8 million in 2022, then climbed by 20.62% to $370.0 million in 2023, then surged by 66.44% to $615.9 million in 2024.